GlobeNewswire Inc.··Not SpecifiedJuvenescence Advances PAI-1 Program With Phase 1 Success, Expands Leadership Team
Juvenescence completes Phase 1 trial of PAI-1 inhibitor MDI-2517 with positive safety results. Company expands leadership and plans Phase 2 study in late 2026.
PFEbiotechclinical development